Cooper Companies

The Cooper Companies lowered its fiscal 2026 revenue and adjusted EPS guidance after weaker-than-expected contact lens demand weighed on CooperVision; Q3 revenue was $1.07 billion versus $1.10 billion expected while adjusted EPS of $1.15 beat estimates. Management cited U.S. channel inventory reductions that are expected to continue into Q4 and now forecasts CooperVision organic growth of 1%–2% for fiscal 2026 (Q4: -2% to 0%). The company completed a strategic review and will retain CooperSurgical, increased its share buyback authorization to $3 billion, and highlighted strong free cash flow and product investment as potential supports if demand normalizes. » Więcej na finance.yahoo.com

Cooper Companies reported Q3 revenue of $1.07 billion, missing consensus, while adjusted EPS of $1.15 slightly beat. Management cut the Q4 outlook to $1.057–1.080 billion (organic growth 0–2%), primarily pressured by inventory destocking in CooperVision’s U.S. distribution channel. The board decided not to sell CooperSurgical after a strategic review, and analysts reacted with downgrades and significantly lower price targets. An increase in the buyback authorization to $3 billion and a record free cash flow of $273 million failed to offset the negative market response. » Więcej na de.investing.com

Cooper Companies reported non-GAAP earnings per share of $1.15 for Q3 2026 (above the $1.12 consensus), while revenue of $1.07 billion missed the $1.1 billion forecast. The stock fell sharply in regular trading and declined further in after-hours trading as investors reacted with concern to weaker sales, accelerated inventory drawdown at CooperVision and a cautious near-term outlook. Positive highlights include a record free cash flow of $273 million and an increase of the share repurchase authorization by $1 billion, but management lowered the revenue outlook for CooperVision and expects Q4 revenue of $1.057–1.08 billion and adjusted EPS of $1.05–1.09. » Więcej na de.investing.com